AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca core operating profit ($M) ($M)
Form 6-K Quarterly & Form 20-F Reported-to-Core Reconciliation
Latest, FY2025
18,478
Period ended Dec 31, 2025
Change on a year earlier
+9.2%
16,928 in FY2024
History
6 years
Since FY2020
Sources
6
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Core operating profit ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 18,478 | +9.2% | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2024 | Dec 31, 2024 | 16,928 | +16.5% | Form 6-K FY2024Q4 Earnings Release ↗ |
| FY2023 | Dec 31, 2023 | 14,534 | +8.9% | Form 6-K FY2023Q4 Earnings Release ↗ |
| FY2022 | Dec 31, 2022 | 13,350 | +34.5% | Form 6-K FY2022Q4 Earnings Release ↗ |
| FY2021 | Dec 31, 2021 | 9,928 | +35.3% | Form 6-K FY2021Q4 Earnings Release ↗ |
| FY2020 | Dec 31, 2020 | 7,340 | – | Form 6-K FY2020Q4 Earnings Release ↗ |
Breakdown
What makes up core operating profit ($m)
- Core operating margin (% of total revenue)31.0% · FY2025
- Core operating profit YoY actual (%)9.0% · FY2025
- Core operating profit YoY CER (%)9.0% · FY2025
- Reported (IFRS) operating profit ($M)13,743 · FY2025
- Reported (IFRS) operating margin (%)23.0% · FY2025
- Core adjustment — Total restructuring charges ($M)-237 · FY2025
- Core adjustment — Intangible asset amortisation & impairments ($M)-4,327 · FY2025
Cite this data
StockData. (2026). AstraZeneca Core operating profit ($M) ($M), annual FY2020–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/core_op_profit
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.